Clinical Trial Update: Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Completed Phase 1/2 trial evaluating H3B-6545 in women with locally advanced or metastatic ER-positive, HER2-negative breast cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• H3B-6545

Snippet

Sponsor: Eisai Inc. | Conditions: Breast Neoplasms, Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-02-25